Search

Displaying results 6641 - 6650 of 10000 in total
  1. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

  2. Drug

    Ginseng

    go.drugbank.com/drugs/DB01404
    ApprovedInvestigationalNutraceutical

    Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties

    Synonyms: Ren shen, Ren seng rootMixtures: GINSENG-E CAPSULE
  3. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    D-proline is an isomer of the naturally occurring amino acid, L-Proline. D-amino acids have been found in relatively high abundance in human plasma and saliva [A19262].

  4. Drug

    TBX-3400

    go.drugbank.com/drugs/DB17370
    Investigational

    TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.

  5. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    [A225691, A225696] This drug is used in the treatment of thrombocytopenia.

  6. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  7. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  8. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in

  9. Drug

    Tixocortol

    go.drugbank.com/drugs/DB09091
    ApprovedWithdrawn

    Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...

  10. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.